Meet Oliver Morton-Evans: Co-founder of Neuromersiv, Revolutionizing Rehabilitation Therapy with VR
Oliver Morton-Evans, Chief Operating Officer at Neuromersiv was inspired to start a MedTech startup by combining his background in producing immersive Virtual Reality experiences and his lived experience with a lifelong disability.
With a background in producing award-winning animation and immersive VR content, Oliver brings a unique perspective to the healthcare industry. Before co-founding Neuromersiv, Oliver and co-founder Anshul Dayal ran an award-winning animation and VR production studio creating immersive experiences for KPMG and Miele. He also produced digital content for The Wiggles for several years.
Neuromersiv is making a significant impact in the healthcare industry by tackling the issues arising from standard rehabilitation therapy.
"There is a lack of therapy compliance which is why it is estimated that 66% of stroke survivors alone do not regain function of their affected arm."
Neuromersiv's solution is Ulysses, an innovative therapy solution that offers engaging and rewarding therapy experiences from the comfort of the user's own home.
Starting a Medtech startup can be a challenging journey. The Neuromersiv team faced many challenges when launching their startup. When they first started, virtual reality technology was at an early stage and was not widely adopted in the healthcare industry.
"The ride can definitely be a rollercoaster, particularly in startups, so choosing co-founders wisely, displaying the resilience and motivation to navigate testing times is particularly important."
-- Oliver Morton-Evans, COO, Neuromersiv
"Have the commercial acumen, know business disciplines and be the most knowledgeable and evidence person in the room."
-- Oliver Morton-Evans, COO, Neuromersiv
The Future of Healthcare and the Role of Technology
"The future of healthcare delivery is definitely home-based telehealth."
Neuromersiv sees the value of patients being able to easily perform their therapy at home, reducing friction for often immobilized people. Neuromersiv's Ulysses VR-based upper limb therapy software has now been successfully included in the Australian TGA and UK MHRA, allowing it to be commercialised in another highly regulated market.
The company is already being used in healthcare clinics, hospitals, and end-users (B2C). The Neuromersiv team is currently raising a $300,000 investment round to begin global distribution and expansion with initial partners in the UK, USA, and India.
Interested investors should contact Anshul Dayal via anshul@neuromersiv.com.